1 – 6 of 6
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Associations between annualized relapse rate and long-term exposure to subcutaneous interferon beta-1a in the Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) long-term follow-up study
2010) 20th Meeting of the European-Neurological-Society In Journal of Neurology 257(Suppl. 1). p.456-456(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Impact of cumulative dose and time on magnetic resonance imaging and clinical outcomes during long-term treatment with subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: exploratory analyses
2009) 25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis In Multiple Sclerosis Journal 15(9). p.126-127(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
(
- Contribution to journal › Article
- 2005
-
Mark
Neutralizing antibodies and efficacy of interferon beta-1a - A 4-year controlled study
(
- Contribution to journal › Article
-
Mark
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria"
(
- Contribution to journal › Article
- 2002
-
Mark
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS
(
- Contribution to journal › Article